Blood Test Study of Circulating Plasma Cells in Multiple Myeloma
Studies a blood test counting circulating plasma cells in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed multiple myeloma who have not had any treatment for it yet and have no history of cancer.
- Age
- 18 to 80 years old
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed multiple myeloma
- Earlier treatment
- No previous treatment for multiple myeloma
Main reasons for not taking part
- Had therapy for multiple myeloma before
- Monoclonal gammopathy of undetermined significance, smoldering myeloma, nonsecretory myeloma, plasma cell leukemia, amyloidosis, Waldenstrom macroglobulinemia or POEMS
- Imminent or emerging infection
- Known to have HIV
- Pregnant, breastfeeding, or planning to become pregnant during the trial
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06228794, who can take part
Where in China
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT06228794
- Record updated
- 21 May 2025
- Original description
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.Read full original descriptionShow less
The Prognostic Value of Circulating Plasma Cells Quantified by Multiparameter Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
Inclusion: Patients must meet all of the following inclusion criteria; Newly diagnosed multiple myeloma patients; Patients without any previous anti-myeloma treatment; Age: 18-80years old (adult); No history of cancer; Informed consent.
Exclusion: Received therapy for multiple myeloma; Imminent or emerging infection; Known to be seropositive for a history of HIV; Patients meeting any of the following exclusion criteria will not be included in the study; Patients diagnosed with monoclonal gammopathy of undetermined significance, smoldering myeloma, nonsecretory myeloma, plasma cell leukemia, amyloidosis, waldenstrom macroglobulinemia or POEMS; A participant is a woman who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial; Known or suspected of not being able to comply with the study protocol.